Medtronic plc, IE00BTN1Y115

Medtronic stock: $380 million Contego acquisition planned

Published on 11/17/2026 at 11:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Medtronic stock is in focus after the company announced plans to acquire Contego Medical. The deal targets carotid and peripheral vascular therapies.

Contego deal expands vascular portfolio

  • Medtronic plans to acquire Contego Medical, subject to customary closing conditions.
  • The transaction adds carotid revascularization and peripheral thrombectomy technologies to Medtronic's cardiovascular portfolio.
  • Medtronic expects the transaction to be minimally dilutive to adjusted EPS in fiscal 2027 and fiscal 2028.
Medtronic plc, IE00BTN1Y115, Illustration mit AI erstellt.

Medtronic announced on Monday, November 16, 2026, that it intends to acquire Contego Medical, a privately held medical-device company focused on carotid artery disease and peripheral thrombectomy. The company announced the planned transaction in a Medtronic press release.

Medtronic said the acquisition is valued at 380 million US dollars, with potential payments after closing. The company expects to complete the transaction in the third quarter of its fiscal year, subject to customary closing conditions. The announcement describes an agreement in progress, not a completed acquisition.

Portfolio broadens in vascular care

The planned deal includes Contego's Neuroguard IEP Direct System, which Medtronic said recently received FDA approval. The system combines transcarotid artery revascularization with integrated embolic protection and flow reversal. Contego also brings Excipio thrombectomy devices, which complement Medtronic's Liberant thrombectomy system in peripheral vascular disease.

Medtronic said the transaction builds on an exclusive US distribution agreement with Contego announced in January 2025. David Moeller, president of Medtronic Peripheral Vascular Health, said the acquisition is intended to strengthen the company's position in carotid artery treatment. Contego chief executive Ravish Sachar described the deal as a deeper partnership.

Limited near-term earnings effect

Medtronic expects the acquisition to be minimally dilutive to adjusted earnings per share in fiscal 2027 and fiscal 2028, and neutral to accretive thereafter. That outlook gives investors a near-term integration and earnings marker while the strategic rationale rests on expanding access to carotid and peripheral vascular technologies.

In the PERFORMANCE III study cited by Medtronic, the Neuroguard IEP Direct System recorded zero strokes, zero neurological deaths, zero cranial nerve injuries and zero myocardial infarctions at 30 days. These study outcomes describe the cited patient group and are not a forecast for the combined business.

Medtronic stock traded at 94.43 euros on Lang & Schwarz at 11:46 CET on Tuesday, November 17, 2026.

Medtronic plc stock

  • Company: Medtronic plc
  • ISIN: IE00BTN1Y115
  • Ticker: MDT
  • Price: 94.43 euros on Lang & Schwarz, Tuesday, November 17, 2026, 11:46 CET
  • Transaction: Planned acquisition of Contego Medical

In the United States, broader equity trading is tracked through the S&P 500.

More news and analyses on Medtronic plc stock

Disclaimer...
en | IE00BTN1Y115 | MEDTRONIC PLC | boerse | 70526160 | bgmi